Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person9
Venrock Healthcare Capital Partners III, L.P.
Company
1607 Capital Partners, LLC
Company
Centurium Capital Partners 2018, L.P.
Company
Durable Capital Partners LP
Company
NewLake Capital Partners, Inc.
Company
P3 Health Partners Inc.
Company
Hill Path Capital Co-Investment Partners LP
Company
Thunder Bridge Capital Partners V, Ltd.
Company
QUMRA CAPITAL II, L.P.
Company
Primary record12
Entera Bio Ltd. filed SCHEDULE 13G
(the "SEC") on October 14, 2026. Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting P
Lycia Therapeutics, Inc. filed SCHEDULE 13G
(the "SEC") on October 23, 2026. Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting P
Frazier Life Sciences Acquisition Corp. II filed SCHEDULE 13G
(the "SEC") on October 14, 2026. Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting P
X4 Pharmaceuticals, Inc filed SCHEDULE 13G
(the "SEC") on August 6, 2026. Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Per
Oruka Therapeutics, Inc. filed SCHEDULE 13G/A
(the "SEC") on May 13, 2026, (ii) 800,433 shares of common stock issued upon the exercise of Warrants by the Reporting Persons after April 30, 2026, and (iii) 408,524 shares of common stock issuable upon the exercise of
Artiva Biotherapeutics, Inc. filed SCHEDULE 13G/A
(the "SEC") on May 8, 2026, and (ii) 23,871,526 shares of common stock issued by the Issuer on May 11, 2026, as reported in the Issuer's Prospectus Supplement filed with the SEC on May 8, 2026. Row 5 of each Reporting Pe
Jade Biosciences, Inc. filed SCHEDULE 13G/A
(the "SEC") on May 7, 2026, (ii) 1,062,309 shares of common stock issued upon the exercise of Warrants by the Reporting Persons after May 1, 2026, (iii) 10,000,000 shares of common stock issued by the Issuer on June 5, 2
Venrock Healthcare Capital Partners III, L.P. filed SCHEDULE 13G/A
(the "SEC") on May 13, 2026, and (ii) 2,634,651 shares of common stock issuable upon the exercise of the Pre-Funded Warrants. Due to field limitations of the EDGAR filing system, the percentage listed in row 11 of each R
Adlai Nortye Ltd. filed SCHEDULE 13G/A
(the "SEC") on July 20, 2026. Row 5 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Pe
TENAX THERAPEUTICS, INC. filed SCHEDULE 13G/A
(the "SEC") on July 31, 2026, and (ii) 1,574,892 shares of common stock issuable upon the exercise of the Warrants. Row 5 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to vote or
KalVista Pharmaceuticals, Inc. filed SCHEDULE 13G/A
0001231919-26-000933.txt : 20260814 SCHEDULE 13G/A 1 primary_doc.xml X0202 SCHEDULE 13G/A 0001104659-23-002259 0001738048 XXXXXXXX LIVE 4 Common Stock, $0.001 par value per share 06/30/2026 0001348911 KalVista Pharmaceut
Venrock Healthcare Capital Partners III, L.P. filed SCHEDULE 13G/A
0001231919-26-000931.txt : 20260814 SCHEDULE 13G/A 1 primary_doc.xml X0202 SCHEDULE 13G/A 0001104659-24-027508 0001738048 XXXXXXXX LIVE 4 Common Shares 06/30/2026 0001980845 enGene Holdings Inc. 29286M105 4868 Rue Levy,